Journal of International Oncology ›› 2023, Vol. 50 ›› Issue (10): 614-617.doi: 10.3760/cma.j.cn371439-20230612-00116
• Original Articles • Previous Articles Next Articles
Qian Weiwei1, Xu Shen1, Kong Qi2()
Received:
2023-06-12
Revised:
2023-09-09
Online:
2023-10-08
Published:
2023-11-08
Contact:
Kong Qi
E-mail:1553981821@qq.com
Supported by:
Qian Weiwei, Xu Shen, Kong Qi. Differential diagnosis value of D-dimer before operation in renal oncocytoma and chromophobe renal cell carcinoma[J]. Journal of International Oncology, 2023, 50(10): 614-617.
"
临床特征 | RO组(n=15) | Ch-RCC组(n=32) | χ2/t值 | P值 |
---|---|---|---|---|
性别 | ||||
男 | 6(40.00) | 16(50.00) | 0.41 | 0.522 |
女 | 9(60.00) | 16(50.00) | ||
年龄(岁) | 55.73±0.51 | 53.84±12.19 | 0.50 | 0.618 |
高血压 | ||||
有 | 3(20.00) | 8(25.00) | <0.01 | 0.994 |
无 | 12(80.00) | 24(75.00) | ||
糖尿病 | ||||
有 | 1(6.67) | 1(3.13) | 0.541 | |
无 | 14(93.33) | 31(96.87) | ||
吸烟史 | ||||
有 | 1(6.67) | 9(28.13) | 1.67 | 0.196 |
无 | 14(93.33) | 23(71.87) | ||
肿瘤侧别 | ||||
左 | 8(53.33) | 13(40.63) | 0.67 | 0.414 |
右 | 7(46.67) | 19(59.37) |
"
指标 | RO组(n=15) | Ch-RCC组(n=32) | t/Z值 | P值 |
---|---|---|---|---|
血红蛋白(g/L) | 124.40±14.46 | 133.38±19.22 | -1.61 | 0.116 |
血小板(×109/L) | 232.53±77.51 | 227.50±55.17 | 0.26 | 0.800 |
白细胞(×109/L) | 5.70±1.84 | 5.66±1.31 | 0.10 | 0.921 |
中性粒细胞 (×109/L) | 2.98±0.87 | 3.26±1.07 | -0.87 | 0.390 |
淋巴细胞 (×109/L) | 1.59(1.47,1.74) | 1.69(1.34,1.90) | 0.82 | 0.418 |
单核细胞 (×109/L) | 0.33(0.28,0.49) | 0.44(0.40,0.49) | 1.43 | 0.153 |
中性粒细胞与 淋巴细胞比值 | 1.94(1.62,2.15) | 1.90(1.42,2.42) | 0.09 | 0.927 |
血小板与淋巴 细胞比值 | 150.22±47.09 | 143.89±48.48 | 0.42 | 0.676 |
淋巴细胞与 单核细胞比值 | 3.89(2.85,6.13) | 3.54(3.02,4.48) | -0.96 | 0.338 |
D二聚体(μg/ml) | 0.21(0.19,0.27) | 0.47(0.29,0.77) | 4.44 | <0.001 |
[1] |
Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European association of urology guidelines on renal cell carcinoma: the 2022 update[J]. Eur Urol, 2022, 82(4): 399-410. DOI: 10.1016/j.eururo.2022.03.006.
pmid: 35346519 |
[2] |
He X, Huang T, Xue Y, et al. Association of preoperative plasma D-dimmer and fibrinogen and renal cell carcinoma outcome[J]. J Cancer, 2019, 10(17): 4096-4105. DOI: 10.7150/jca.31173.
pmid: 31417654 |
[3] |
Wang J, Li H, Xu R, et al. The MLR, NLR, PLR and D-dimer are associated with clinical outcome in lung cancer patients treated with surgery[J]. BMC Pulm Med, 2022, 22(1): 104. DOI: 10.1186/s12890-022-01901-7.
pmid: 35337299 |
[4] |
Otsu T, Hayashi M, Takami H, et al. High preoperative serum D-dimer predicts unfavorable survival outcomes for pancreatic cancer patients[J]. Anticancer Res, 2023, 43(7): 3173-3181. DOI: 10.21873/anticanres.16491.
pmid: 37352000 |
[5] | Ren Z, Yang J, Liang J, et al. Monitoring of postoperative neutrophil-to-lymphocyte ratio, D-dimer, and CA153 in: diagnostic value for recurrent and metastatic breast cancer[J]. Front Surg, 2022, 9: 927491. DOI: 10.3389/fsurg.2022.927491. |
[6] |
Li Y, Huang X, Xia Y, et al. Value of radiomics in differential diagnosis of chromophobe renal cell carcinoma and renal oncocytoma[J]. Abdom Radiol (NY), 2020, 45(10): 3193-3201. DOI: 10.1007/s00261-019-02269-9.
pmid: 31664486 |
[7] |
Qu J, Zhang Q, Song X, et al. CT differentiation of the oncocytoma and renal cell carcinoma based on peripheral tumor parenchyma and central hypodense area characterisation[J]. BMC Med Imaging, 2023, 23(1): 16. DOI: 10.1186/s12880-023-00972-0.
pmid: 36707788 |
[8] | Li X, Ma Q, Nie P, et al. A CT-based radiomics nomogram for differentiation of renal oncocytoma and chromophobe renal cell carcinoma with a central scar-matched study[J]. Br J Radiol, 2022, 95(1129): 20210534. DOI: 10.1259/bjr.20210534. |
[9] | 王国杰, 秦培鑫, 陈相猛, 等. 病灶大小对肾脏嗜酸细胞腺瘤及嫌色细胞癌CT征象的影响[J]. 中华介入放射学电子杂志, 2022, 10(1): 56-60. DOI: 10.3877/cma.j.issn.2095-5782.2022.01.010. |
[10] | Uchida Y, Yoshida S, Arita Y, et al. Apparent diffusion coefficient map-based texture analysis for the differentiation of chromophobe renal cell carcinoma from renal oncocytoma[J]. Diagnostics (Basel), 2022, 12(4): 817. DOI: 10.3390/diagnostics12040817. |
[11] |
Hara K, Aoyama T, Hayashi T, et al. Postoperative D-dimer elevation affects tumor recurrence and the long-term survival in gastric cancer patients who undergo gastrectomy[J]. Int J Clin Oncol, 2020, 25(4): 584-594. DOI: 10.1007/s10147-019-01603-x.
pmid: 31865480 |
[12] | Li X, Shu K, Zhou J, et al. Preoperative plasma fibrinogen and D-dimer as prognostic biomarkers for non-muscle-invasive bladder cancer[J]. Clin Genitourin Cancer, 2020, 18(1): 11-19.e1. DOI: 10.1016/j.clgc.2019.10.025. |
[13] |
Watanabe A, Araki K, Harimoto N, et al. D-dimer predicts postoperative recurrence and prognosis in patients with liver metastasis of colorectal cancer[J]. Int J Clin Oncol, 2018, 23(4): 689-697. DOI: 10.1007/s10147-018-1271-x.
pmid: 29574651 |
[14] | Dirix LY, Oeyen S, Buys A, et al. Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer[J]. Breast Cancer Res Treat, 2022, 192(3): 583-591. DOI: 10.1007/s10549-021-06484-1. |
[15] | Tieken C, Versteeg HH. Anticoagulants versus cancer[J]. Thromb Res, 2016, 140(Suppl 1): S148-S153. DOI: 10.1016/S0049-3848(16)30114-1. |
[16] |
Dai H, Zhou H, Sun Y, et al. D-dimer as a potential clinical marker for predicting metastasis and progression in cancer[J]. Biomed Rep, 2018, 9(5): 453-457. DOI: 10.3892/br.2018.1151.
pmid: 30402229 |
[17] | Guo J, Gao Y, Gong Z, et al. Plasma D-dimer level correlates with age, metastasis, recurrence, tumor-node-metastasis classification (TNM), and treatment of non-small-cell lung cancer (NSCLC) patients[J]. Biomed Res Int, 2021, 2021: 9623571. DOI: 10.1155/2021/9623571. |
[18] |
Erdem S, Amasyali AS, Aytac O, et al. Increased preoperative levels of plasma fibrinogen and D dimer in patients with renal cell carcinoma is associated with poor survival and adverse tumor characteristics[J]. Urol Oncol, 2014, 32(7): 1031-1040. DOI: 10.1016/j.urolonc.2014.03.013.
pmid: 25027687 |
[1] | Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[2] | Wang Jing, Xu Wenting. Value of NLR, CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526. |
[3] | Xiong Min, Chen Yi, Wang Jianbo. Value of CT radiomic features in differential diagnosis of lung metastases [J]. Journal of International Oncology, 2023, 50(4): 208-213. |
[4] | Wu Guang, Yu Yuandong, Chen Ping. Clinical observation of apatinib mesylate in the treatment of metastatic renal carcinoma [J]. Journal of International Oncology, 2021, 48(11): 655-659. |
[5] | Wang Jiali, Han Dong, Chen Ying, Zhang Yamin, Ai Meimei. Construction of a nomogram of overall survival of patients with clear cell renal cell carcinoma based on preoperative CT findings [J]. Journal of International Oncology, 2020, 47(8): 480-486. |
[6] | Han Jing, Yuan Shuai, Pu Yan, Liu Huibin. Analysis of SKA1 gene expression in clear cell renal cell carcinoma and its clinical significance based on bioinformatics database [J]. Journal of International Oncology, 2020, 47(10): 598-605. |
[7] | Chen Liang, Peng Min, Weng Yiming, Song Qibin. New strategies for the treatment of clear cell renal cell carcinoma: target the metabolic reprogramming [J]. Journal of International Oncology, 2019, 46(7): 443-446. |
[8] | Xiong Bobo, Zhang Jinsong, Li Ning, Wang Haifeng, Zuo Yigang, Wang Jiansong. Molecular targeted therapy for advanced kidney cancer [J]. Journal of International Oncology, 2019, 46(12): 705-710. |
[9] |
Cai Liang, Shen Yali.
Application of stereotactic body radiation therapy in advanced renal cell carcinoma [J]. Journal of International Oncology, 2019, 46(10): 627-630. |
[10] | Ye Zhihua, Huang Geng, Fu Jinlun, Gui Dingwen. Effects of miR-1291 on the cell cycle and proliferation of renal cell carcinoma by regulating the expression of Zinc finger protein 8 gene [J]. Journal of International Oncology, 2018, 45(3): 129-133. |
[11] | LI Jin-Tao, LI Jin-Feng. Expressions and clinical significance of matrix metalloproteinase-9 and tissue inhibitor of metallopro-teinase-1 in renal carcinoma [J]. Journal of International Oncology, 2018, 45(2): 92-95. |
[12] | Huang Geng, Jiang Weidong, Mao Qing, Gui Dingwen. Effect of exogenous dsRNA on expression of p21 in renal clear cell carcinoma cells [J]. Journal of International Oncology, 2017, 44(7): 481-484. |
[13] | Zhou Qidong, Jiang Guangliang, Xu Ke. Research progress of glucocorticoid receptor in urological malignant tumors [J]. Journal of International Oncology, 2017, 44(6): 476-. |
[14] | Xiaoliang, Luo Xu, Liu Ruming. Expression and relationship between hepaCAM protein and multidrug resistance protein in renal carcinoma [J]. Journal of International Oncology, 2016, 43(8): 584-587. |
[15] | Dai Xing, Ba Nan, Yan Lin. Study on the difference of sunitinib and sorafenib as firstline treatment in advanced renal carcinoma [J]. Journal of International Oncology, 2016, 43(1): 8-11. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 51
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 65
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||